Profarma reported its financial results for the fourth quarter and full year of 2013, highlighting growth in revenues and profits. The company also announced a strategic partnership with AmerisourceBergen, including a capital increase and joint venture, to expand in the pharmaceutical specialties market. Profarma expects the deal to accelerate its growth and strengthen its brand through new business opportunities and synergies with AmerisourceBergen's expertise.
The document provides financial information for Profarma's 2Q17 earnings release. Key highlights include:
- Consolidated sales grew 6.7% year-over-year led by 55.4% growth in retail sales.
- Pharma distribution sales increased 3.9% with 10% growth in independent customer segment. Cash cycle was shortened by 16.8 days.
- Specialties sales grew 3.6% in 1H17 year-over-year with vaccine sales up 40.2% and generics category up 6.3%. Operating expenses declined 0.3 percentage points.
- Retail EBITDA margin improved compared to prior periods through expense optimization initiatives.
The document discusses various strategic management tools and concepts including:
- Types of business strategies such as market penetration, product development, diversification, integration, and retrenchment.
- Analytical tools for strategic analysis including SWOT, BCG matrix, SPACE matrix, IE matrix, and Grand Strategy matrix.
- The setting of strategic objectives including examples of strategic objectives related to market share and financial objectives related to revenues, profits, and other metrics.
This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
The SGS Group performed solidly in the first semester with total revenue exceeding CHF 3.0 billion and is on track to deliver the revenue growth projected in the 2020 strategic plan.
The Group grew the top line by 4.9% on a constant currency basis, of which 3.4% was organic, with the remainder being associated with recent acquisitions. On a reported basis, Group revenue increased by 5.0%.
The strong growth was mainly attributable to the non-energy related businesses and once again demonstrated the strength of the Group’s well balanced portfolio.
This document outlines Pfizer's plans to acquire Wyeth to create the world's premier biopharmaceutical company. The acquisition will diversify Pfizer's portfolio and strengthen its leadership in key therapeutic areas and geographies. Pfizer expects the deal to advance its strategic priorities and deliver $2 billion in cost savings by 2011 on top of $4 billion in synergies from the transaction. The all-cash-and-stock deal is valued at $68 billion and will be funded through cash, debt, and Pfizer stock.
This document is a report on the functions of a corporate financial organization manager for a public limited company. It includes an introduction, organizational profile of Beximco Pharmaceuticals Ltd, work responsibilities of team members, findings and analysis of investment decisions, financing decisions, working capital management and dividend decisions. The conclusion provides an overall analysis and recommendations to improve Beximco Pharma's performance.
The document provides financial information for Profarma's 2Q17 earnings release. Key highlights include:
- Consolidated sales grew 6.7% year-over-year led by 55.4% growth in retail sales.
- Pharma distribution sales increased 3.9% with 10% growth in independent customer segment. Cash cycle was shortened by 16.8 days.
- Specialties sales grew 3.6% in 1H17 year-over-year with vaccine sales up 40.2% and generics category up 6.3%. Operating expenses declined 0.3 percentage points.
- Retail EBITDA margin improved compared to prior periods through expense optimization initiatives.
The document discusses various strategic management tools and concepts including:
- Types of business strategies such as market penetration, product development, diversification, integration, and retrenchment.
- Analytical tools for strategic analysis including SWOT, BCG matrix, SPACE matrix, IE matrix, and Grand Strategy matrix.
- The setting of strategic objectives including examples of strategic objectives related to market share and financial objectives related to revenues, profits, and other metrics.
This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
The SGS Group performed solidly in the first semester with total revenue exceeding CHF 3.0 billion and is on track to deliver the revenue growth projected in the 2020 strategic plan.
The Group grew the top line by 4.9% on a constant currency basis, of which 3.4% was organic, with the remainder being associated with recent acquisitions. On a reported basis, Group revenue increased by 5.0%.
The strong growth was mainly attributable to the non-energy related businesses and once again demonstrated the strength of the Group’s well balanced portfolio.
This document outlines Pfizer's plans to acquire Wyeth to create the world's premier biopharmaceutical company. The acquisition will diversify Pfizer's portfolio and strengthen its leadership in key therapeutic areas and geographies. Pfizer expects the deal to advance its strategic priorities and deliver $2 billion in cost savings by 2011 on top of $4 billion in synergies from the transaction. The all-cash-and-stock deal is valued at $68 billion and will be funded through cash, debt, and Pfizer stock.
This document is a report on the functions of a corporate financial organization manager for a public limited company. It includes an introduction, organizational profile of Beximco Pharmaceuticals Ltd, work responsibilities of team members, findings and analysis of investment decisions, financing decisions, working capital management and dividend decisions. The conclusion provides an overall analysis and recommendations to improve Beximco Pharma's performance.
Investor Handout Meet Management 2014 in LeverkusenBayer
This document provides a summary of a presentation given by Marijn Dekkers, CEO of Bayer, at a management conference on March 12, 2014 in Leverkusen. The presentation discusses Bayer's strong financial performance from 2010-2013, with sales, core EPS and adjusted EBITDA all growing at a CAGR of 5-10% during this period. It highlights the company's focus on innovation and new product launches across its businesses in pharmaceuticals, consumer health, crop science and materials science. The presentation outlines Bayer's strategic goals for continued sales and earnings growth at each division through 2016.
The document is a report submitted to a lecturer at the University of Dhaka on supply chain management at Orion Pharma Ltd. It discusses Orion Pharma's facilities, inventory management, transportation systems, information collection, and sourcing strategies. The company has two production factories located in Dhaka and Narayanganj. It uses a flexible facility structure and keeps average inventory levels with minimal safety stock. Orion Pharma transports products via truck and has its own transportation network. It collects market information through a survey team and purchases reports from external organizations. The company sources raw materials from both domestic and international suppliers.
This document provides an overview of Bayer HealthCare as of March 2011. It discusses the company's structure, key financial data, business areas, research and development activities, and goals for strengthening its position in pharmaceuticals, consumer health, and emerging markets. Bayer HealthCare aims to be a leading diversified healthcare company through innovation, building strong brands, and expanding in high-growth areas.
Merck delivered on its financial targets for 2013 with sales of €10.7 billion, a 10% increase in EBITDA pre to €3.253 billion, and a 15% rise in EPS pre to €8.78. Organic growth of 4% was overshadowed by currency headwinds. Merck Serono and Merck Millipore contributed most to organic sales growth. Profitability increased across all divisions due to cost savings, better resource allocation, and portfolio changes. Merck is accelerating its cost savings program and remains on track to realize €385 million in annual savings by 2017.
Sanofi is a multinational pharmaceutical company. One problem they face is employee retention in the same positions due to acquisitions. To overcome this, Sanofi invests in training and developing employees through programs like Future Access, Work Day, and Ashbal. These initiatives aim to provide employees with new skills and opportunities for career growth. Sanofi evaluates the success of their training strategies using Kirkpatrick's four-level model, looking at reaction, learning, application on the job, and impact on business results. The goal is to increase employee loyalty and encourage high performance through learning and development.
This is a basic report of BEXIMCO pharma industry. Only basic tools and topics of management were used to prepare this report. This report might help the students who are doing MGT 210 COURSE in North South University of BANGLADESH.
Merck reported solid Q1 2014 results, with 4% organic sales growth offset by 5% negative currency effects. All divisions posted organic growth. EBITDA pre increased slightly to €807 million despite royalty income reduction and currency headwinds. EPS pre was up 9% to €2.31. Guidance for 2014 forecasts sales of €10.9-11.1 billion and EBITDA pre of €3.3-3.4 billion.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
Beximco Pharmaceuticals Ltd. is the largest pharmaceutical company in Bangladesh. It was established in 1976 and began operations in 1980 by manufacturing and marketing imported drugs under licensing agreements. In 1983, Beximco began producing its own formulations and launched exports in 1992. Today, Beximco manufactures over 500 generic drug products and has over 2,700 employees. It has received several national awards for export excellence. The report analyzes Beximco's financial performance based on ratio analysis using data from its annual reports and interviews.
The document discusses research and development (R&D) ratios and Sanofi-Aventis' R&D expenditures over time. It notes that Sanofi-Aventis was formed through the merger of Sanofi and Aventis in 2004. From 2001-2004, both companies maintained an R&D intensity of around 16%, but in 2004 after the merger, R&D intensity increased dramatically to 50% as R&D expenditures rose significantly that year. The document also presents Sanofi-Aventis' continued R&D spending and intensity levels from 2004-2008.
Group G's presentation topic is a marketing mix analysis of Incepta Pharmaceuticals Ltd. The document provides background information on Incepta, including that it is a leading pharmaceutical company in Bangladesh established in 1999. It also discusses Incepta's competitors, market share, products, pricing, distribution channels, inventory management, transportation, warehousing, and promotional activities.
The document is a ratio analysis report on Beximco Pharmaceuticals Ltd, one of the largest pharmaceutical companies in Bangladesh. It provides an overview of the pharmaceutical industry in Bangladesh and Beximco Pharma. It discusses the objectives, methodology and limitations of the ratio analysis. The report covers theoretical concepts of ratio analysis including categories like liquidity, profitability, capital structure and formulas to calculate relevant ratios. Financial data for the years 2006-2010 is presented to analyze Beximco Pharma's cash position, liquidity, profitability and other ratios.
The opportunities for the Indian pharmaceutical industry are immense but increasing competition, increasing regulatory pressures and stringent price control means that companies need to constantly improve their costs and service levels. Supply chain efficiencies will play a crucial role going forward and will become the key differentiator for companies. Companies will therefore need to adopt an approach that encompasses strategic, tactical and operational interventions to remain competitive and create value for their customers
The document provides highlights from Profarma's 2Q15 earnings release. It discusses the company's consolidated performance, including a 9.6% increase in gross revenues. It also summarizes key metrics and growth for each of Profarma's divisions: Pharmaceutical Distribution, Specialties, and Retail. The Retail section specifically calls out sales increases and improvements in margins for the Tamoio and Drogasmil/Farmalife chains. The document concludes with an analyst coverage section listing analysts that follow Profarma.
This document provides an overview of the human resource practices and policies of Beximco Pharmaceuticals Limited, a leading pharmaceutical company in Bangladesh. It discusses Beximco's mission, vision, core values, organizational structure, departments, recruitment process, performance appraisals, training programs, compensation policies, and employee relations practices. The summary highlights that Beximco has over 500 pharmaceutical products and 2800 employees across 12 departments. It also outlines Beximco's focus on quality, customer satisfaction, and developing its people as reflected in its human resources policies and practices.
Bayer reported strong Q3 2015 results, with sales and earnings increasing year-over-year across most business segments. Key highlights included a successful IPO of Covestro, organic growth at Pharma driven by new product launches, solid performance at Consumer Health, and CropScience demonstrating resilience in a challenging market environment. For full-year 2015, Bayer reiterated its guidance for low-single digit sales growth and high-teens percentage increases in EBITDA and core EPS.
Walgreens Boots Alliance was created in December 2014 through the combination of Walgreens and Alliance Boots, bringing together two leading healthcare companies with complementary geographic footprints and over 100 years of experience in pharmaceutical wholesaling and community pharmacy care. The transaction created a global leader in pharmacy-led health and wellbeing with over 13,100 stores across 11 countries and one of the largest pharmaceutical wholesale networks reaching over 200,000 pharmacies, doctors, and health centers each year in 19 countries.
This document summarizes initiatives by Walgreens interns to improve the customer experience in pharmacy, drive front end sales, and gain experience through work activities. The interns implemented programs like senior days, immunization outreach, and incentive coupons to increase pharmacy services and sales. Their incentive coupon pilot increased front end revenue by over $9,000 across 4 stores. The interns also participated in workshadowing, store visits, and a retail symposium to immerse themselves in Walgreens operations.
The document discusses medication therapy management (MTM) services and developing an MTM practice. It defines MTM as patient care services established by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The core elements of an MTM service model are identified as medication therapy review, personal medication record, medication-related action plan, intervention/referral, and documentation/follow-up. Additionally, the document discusses current MTM legislation, skills needed for MTM, and how to become an MTM provider through needs assessment, SWOT analysis, service planning, financial justification, payment, and program evaluation.
The document provides an overview of Walgreens' organizational structure, culture, and strategies. It discusses Walgreens' mission to be a trusted provider of pharmacy and wellness solutions. It describes Walgreens' hierarchical structure with regions, districts, and stores led by executives, vice presidents, and managers. The document also summarizes Walgreens' emphasis on customer service, convenience, employee engagement, and social responsibility including supporting diversity and community. Finally, it analyzes Walgreens' strategic decisions to open Wellness Experience stores and acquire Alliance Boots to become a global enterprise.
Investor Handout Meet Management 2014 in LeverkusenBayer
This document provides a summary of a presentation given by Marijn Dekkers, CEO of Bayer, at a management conference on March 12, 2014 in Leverkusen. The presentation discusses Bayer's strong financial performance from 2010-2013, with sales, core EPS and adjusted EBITDA all growing at a CAGR of 5-10% during this period. It highlights the company's focus on innovation and new product launches across its businesses in pharmaceuticals, consumer health, crop science and materials science. The presentation outlines Bayer's strategic goals for continued sales and earnings growth at each division through 2016.
The document is a report submitted to a lecturer at the University of Dhaka on supply chain management at Orion Pharma Ltd. It discusses Orion Pharma's facilities, inventory management, transportation systems, information collection, and sourcing strategies. The company has two production factories located in Dhaka and Narayanganj. It uses a flexible facility structure and keeps average inventory levels with minimal safety stock. Orion Pharma transports products via truck and has its own transportation network. It collects market information through a survey team and purchases reports from external organizations. The company sources raw materials from both domestic and international suppliers.
This document provides an overview of Bayer HealthCare as of March 2011. It discusses the company's structure, key financial data, business areas, research and development activities, and goals for strengthening its position in pharmaceuticals, consumer health, and emerging markets. Bayer HealthCare aims to be a leading diversified healthcare company through innovation, building strong brands, and expanding in high-growth areas.
Merck delivered on its financial targets for 2013 with sales of €10.7 billion, a 10% increase in EBITDA pre to €3.253 billion, and a 15% rise in EPS pre to €8.78. Organic growth of 4% was overshadowed by currency headwinds. Merck Serono and Merck Millipore contributed most to organic sales growth. Profitability increased across all divisions due to cost savings, better resource allocation, and portfolio changes. Merck is accelerating its cost savings program and remains on track to realize €385 million in annual savings by 2017.
Sanofi is a multinational pharmaceutical company. One problem they face is employee retention in the same positions due to acquisitions. To overcome this, Sanofi invests in training and developing employees through programs like Future Access, Work Day, and Ashbal. These initiatives aim to provide employees with new skills and opportunities for career growth. Sanofi evaluates the success of their training strategies using Kirkpatrick's four-level model, looking at reaction, learning, application on the job, and impact on business results. The goal is to increase employee loyalty and encourage high performance through learning and development.
This is a basic report of BEXIMCO pharma industry. Only basic tools and topics of management were used to prepare this report. This report might help the students who are doing MGT 210 COURSE in North South University of BANGLADESH.
Merck reported solid Q1 2014 results, with 4% organic sales growth offset by 5% negative currency effects. All divisions posted organic growth. EBITDA pre increased slightly to €807 million despite royalty income reduction and currency headwinds. EPS pre was up 9% to €2.31. Guidance for 2014 forecasts sales of €10.9-11.1 billion and EBITDA pre of €3.3-3.4 billion.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
Beximco Pharmaceuticals Ltd. is the largest pharmaceutical company in Bangladesh. It was established in 1976 and began operations in 1980 by manufacturing and marketing imported drugs under licensing agreements. In 1983, Beximco began producing its own formulations and launched exports in 1992. Today, Beximco manufactures over 500 generic drug products and has over 2,700 employees. It has received several national awards for export excellence. The report analyzes Beximco's financial performance based on ratio analysis using data from its annual reports and interviews.
The document discusses research and development (R&D) ratios and Sanofi-Aventis' R&D expenditures over time. It notes that Sanofi-Aventis was formed through the merger of Sanofi and Aventis in 2004. From 2001-2004, both companies maintained an R&D intensity of around 16%, but in 2004 after the merger, R&D intensity increased dramatically to 50% as R&D expenditures rose significantly that year. The document also presents Sanofi-Aventis' continued R&D spending and intensity levels from 2004-2008.
Group G's presentation topic is a marketing mix analysis of Incepta Pharmaceuticals Ltd. The document provides background information on Incepta, including that it is a leading pharmaceutical company in Bangladesh established in 1999. It also discusses Incepta's competitors, market share, products, pricing, distribution channels, inventory management, transportation, warehousing, and promotional activities.
The document is a ratio analysis report on Beximco Pharmaceuticals Ltd, one of the largest pharmaceutical companies in Bangladesh. It provides an overview of the pharmaceutical industry in Bangladesh and Beximco Pharma. It discusses the objectives, methodology and limitations of the ratio analysis. The report covers theoretical concepts of ratio analysis including categories like liquidity, profitability, capital structure and formulas to calculate relevant ratios. Financial data for the years 2006-2010 is presented to analyze Beximco Pharma's cash position, liquidity, profitability and other ratios.
The opportunities for the Indian pharmaceutical industry are immense but increasing competition, increasing regulatory pressures and stringent price control means that companies need to constantly improve their costs and service levels. Supply chain efficiencies will play a crucial role going forward and will become the key differentiator for companies. Companies will therefore need to adopt an approach that encompasses strategic, tactical and operational interventions to remain competitive and create value for their customers
The document provides highlights from Profarma's 2Q15 earnings release. It discusses the company's consolidated performance, including a 9.6% increase in gross revenues. It also summarizes key metrics and growth for each of Profarma's divisions: Pharmaceutical Distribution, Specialties, and Retail. The Retail section specifically calls out sales increases and improvements in margins for the Tamoio and Drogasmil/Farmalife chains. The document concludes with an analyst coverage section listing analysts that follow Profarma.
This document provides an overview of the human resource practices and policies of Beximco Pharmaceuticals Limited, a leading pharmaceutical company in Bangladesh. It discusses Beximco's mission, vision, core values, organizational structure, departments, recruitment process, performance appraisals, training programs, compensation policies, and employee relations practices. The summary highlights that Beximco has over 500 pharmaceutical products and 2800 employees across 12 departments. It also outlines Beximco's focus on quality, customer satisfaction, and developing its people as reflected in its human resources policies and practices.
Bayer reported strong Q3 2015 results, with sales and earnings increasing year-over-year across most business segments. Key highlights included a successful IPO of Covestro, organic growth at Pharma driven by new product launches, solid performance at Consumer Health, and CropScience demonstrating resilience in a challenging market environment. For full-year 2015, Bayer reiterated its guidance for low-single digit sales growth and high-teens percentage increases in EBITDA and core EPS.
Walgreens Boots Alliance was created in December 2014 through the combination of Walgreens and Alliance Boots, bringing together two leading healthcare companies with complementary geographic footprints and over 100 years of experience in pharmaceutical wholesaling and community pharmacy care. The transaction created a global leader in pharmacy-led health and wellbeing with over 13,100 stores across 11 countries and one of the largest pharmaceutical wholesale networks reaching over 200,000 pharmacies, doctors, and health centers each year in 19 countries.
This document summarizes initiatives by Walgreens interns to improve the customer experience in pharmacy, drive front end sales, and gain experience through work activities. The interns implemented programs like senior days, immunization outreach, and incentive coupons to increase pharmacy services and sales. Their incentive coupon pilot increased front end revenue by over $9,000 across 4 stores. The interns also participated in workshadowing, store visits, and a retail symposium to immerse themselves in Walgreens operations.
The document discusses medication therapy management (MTM) services and developing an MTM practice. It defines MTM as patient care services established by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The core elements of an MTM service model are identified as medication therapy review, personal medication record, medication-related action plan, intervention/referral, and documentation/follow-up. Additionally, the document discusses current MTM legislation, skills needed for MTM, and how to become an MTM provider through needs assessment, SWOT analysis, service planning, financial justification, payment, and program evaluation.
The document provides an overview of Walgreens' organizational structure, culture, and strategies. It discusses Walgreens' mission to be a trusted provider of pharmacy and wellness solutions. It describes Walgreens' hierarchical structure with regions, districts, and stores led by executives, vice presidents, and managers. The document also summarizes Walgreens' emphasis on customer service, convenience, employee engagement, and social responsibility including supporting diversity and community. Finally, it analyzes Walgreens' strategic decisions to open Wellness Experience stores and acquire Alliance Boots to become a global enterprise.
Charles R. Walgreen opened the first Walgreens store in Chicago in 1901. By 1920, Walgreens had expanded to 44 stores with $1.2 million in annual sales. In 2010, Walgreens became the largest drugstore chain in the US with over 7,500 stores across 50 states. Walgreens pioneered innovations like child resistant packaging and using satellite technology to connect pharmacy systems.
The Walgreens Story: Putting an API Around Their Stores (Webcast)Apigee | Google Cloud
Walgreens made headlines in 2012 by releasing APIs for mobile developers to enable photo printing from smartphones and quickly followed up with an API for prescription drugs. But what's a traditional business like Walgreens doing with an API? Way beyond increased relevance in an Instagram age, the Walgreens story is one of transformation of an entire business model.
Join Joe Rago and Nicholas Eby of Walgreens and Brian Mulloy of Apigee for a discussion of Walgreens' journey through the digital transformation of a century old brick-and-mortar enterprise.
If you can't make to the live webcast, register below and we'll send you a video recording with slides.
We will discuss:
The path to an API - hurdles, decisions, and milestones
- Walgreens APIs - key features and technology
- Developer and partner programs -awareness and integrations
- 3rd Party Developers - gaining awareness and integrations
Hypermarcas provides concise summaries in 3 sentences or less that provide the high level and essential information from the document. The document contains information about Hypermarcas, a Brazilian consumer goods company. It discusses the company's pharma and consumer divisions, financial results, and growth strategies. The company has leadership positions in key pharmaceutical and consumer goods markets in Brazil. It is focused on organic growth through new product development, market expansion, and operational efficiencies during a harvest period. Financial results have been positively impacted by the economic recovery in Brazil and Hypermarcas' restructuring efforts.
Profarma is acquiring Drogaria Rosário for R$173 million. The acquisition will be paid through R$32 million in cash at closing and R$91 million 36 months after closing. The acquisition expands Profarma's retail footprint and positions its d1000 retail division as the 6th largest drugstore chain in Brazil. The acquisition offers synergies through increased scale and bargaining power. Profarma has a track record of successfully integrating and turning around acquisitions like Drogasmil/Farmalife. The Rosário acquisition strengthens Profarma's strategic positioning across multiple divisions.
Profarma's wholesale, specialties, and retail divisions are positioned for continued growth in the Brazilian pharmaceutical market. Global pharmaceutical spending is projected to reach $1.3 trillion by 2018, with emerging markets like Brazil experiencing above-average growth rates. Profarma has a proven track record of organic and acquisition-based expansion in Brazil, and its strategic partnership with AmerisourceBergen provides access to new capabilities and markets.
This document provides an overview of Hypera Pharma's business, including:
- Hypera Pharma has grown organically and through acquisitions to become a leading pharmaceutical company in Brazil, with a focus on branded prescription drugs, generics, and consumer health products.
- The company has three business units focused on different demand channels and an innovation hub that files 30-35 new product submissions annually.
- Hypera Pharma's strategic plan is focused on growing 2-3 percentage points above the market through innovation and commercial execution, while maintaining profitability.
Merck reported strong financial results for fiscal year 2016. Net sales increased 17% to €15.02 billion, driven by organic growth across all regions and the acquisition of Sigma-Aldrich. EBITDA pre increased 24% to €4.49 billion and EPS pre increased 28% to €6.21, both exceeding guidance. All business sectors achieved organic growth, with particularly strong contributions from the Life Science and Healthcare sectors. Merck also reduced net financial debt by 9% and proposed a dividend of €1.20 per share, a 19% increase over the prior year.
The document is a summary of the 2014 Food & Beverage Industry Study by WeiserMazars LLP. It finds that most food and beverage companies anticipated sales growth in 2013 and 2014 due to new customers and improved sales performance. Companies expect costs like labor to rise in 2014. The top concerns for companies are rising commodity costs and food safety. Most companies are prepared for Affordable Care Act requirements and are focusing on process improvement and digital marketing.
This document provides an earnings release and financial highlights for a Brazilian pharmaceutical company for the fourth quarter and full year 2014. Key points include:
- Consolidated EBITDA rose 9.6% to R$87.3 million in 2014, with an EBITDA margin of 2.2% versus 2013.
- Sales increased in the pharmaceutical distribution, specialties, and retail divisions. The retail division benefited from sales growth and store expansion at Drogasmil and Tamoio pharmacies.
- Net losses widened in 2014 due to higher financial expenses, though operating results improved across divisions.
- The company remains focused on acquisitions and integrating companies onto its SAP platform to drive synergies.
This document summarizes Marijn Dekkers' presentation at a Bayer investor conference in New York on June 5, 2014. It discusses Bayer's mission of innovation and customer value, provides an overview of its business portfolio and financial performance, and outlines guidance and aspirations for growth in its pharmaceutical, consumer care, and crop science divisions through 2016. The presentation contains forward-looking statements and disclaims any obligation to update projections.
Bruker Corporation reported its Q4 and full year 2013 financial results. For Q4 2013, revenues increased 7% year-over-year to $552 million driven by 6.2% organic growth. Operating income grew 11% and non-GAAP earnings per share increased 11%. For the full year, revenues grew 3% to $1.84 billion while operating margins declined by around 100 basis points due to currency effects. The company provided guidance for 2014 of 3-4% revenue growth and 10-14% growth in non-GAAP earnings per share.
1) Impax reported financial results for the third quarter of 2016 with generic revenue down 3% year-over-year due to price erosion, partially offset by growth in epinephrine auto-injector and oxymorphone sales.
2) The company provided a business update on growing market share for key generic and brand products through marketing initiatives and new launches, while also facing challenges from industry-wide price declines.
3) Impax discussed its pipeline of generic opportunities and investments in research and development, focusing on expanding its central nervous system franchise and growing products like Rytary, Zomig nasal spray, and Emverm.
This document provides an earnings release and financial highlights for Profarma Group for the 4th quarter and full year of 2015. Key points include:
- Gross revenues increased 10.5% in 2015 driven by growth across all business divisions.
- Consolidated EBITDA grew 31.4% in 2015 with an EBITDA margin of 2.7%.
- The retail division saw same-store sales growth of 15.9% for Drogasmil and 8.8% for Tamoio.
- The specialties division achieved sales growth of 25.9% and an EBITDA increase of 172%.
- Pharmaceutical distribution sales rose 7.3% while EBITDA grew 33
The document provides highlights from Profarma's 1Q14 earnings release. Key points include:
- Sales growth across divisions, with Retail sales up 45.5% and Specialties up 5.4%.
- Implementation of new IT systems in the Retail segment.
- Strategic partnership with AmerisourceBergen to create Profarma Specialty distribution business.
- Overall gross revenues were stable while expenses declined, leading to improved EBITDA margins.
- Cash flow was positively impacted by a reduction in days sales outstanding.
Merck reported solid results for Q1 2016 with net sales increasing 20.5% to €3.665 billion driven by the acquisition of Sigma-Aldrich. Organic sales growth was 4.7% led by strong performance in Life Science and Healthcare. EBITDA pre grew 27% to €1.084 billion due to the Sigma acquisition, end of Rebif commission expenses, and organic growth partially offset by increased R&D investments. Net financial debt decreased nearly €600 million and full-year guidance was reiterated.
The document provides a disclaimer stating that any forward-looking statements are based on management's expectations and are subject to changing market conditions. It also notes that the financial data discussed should be considered for informational purposes only and not as a guarantee of future performance. Additionally, the document states that unaudited information reflects management's interpretation and was prepared for analysis, so additional analysis is needed.
This document provides an overview of Novartis' Q3 2021 results investor presentation. It includes sections on company overview, financial performance, key growth drivers, and an announcement to commence a strategic review of the Sandoz division to maximize shareholder value. The strategic review will explore options ranging from retaining Sandoz to a potential separation, and an update will be provided by the end of 2022.
Impax laboratories credit suisse conference nov 11 2014impax-labs
Impax provides a summary of its dual generic and branded business model, focusing on resolving FDA issues, maximizing both platforms, optimizing R&D, and accelerating business development. It highlights recent generic and branded product launches contributing over $190 million and the growth of Zomig Nasal Spray sales. Impax also outlines its reorganization of R&D to strengthen infrastructure, leverage internal strengths, improve efficiencies, and prioritize quality initiatives within scientific operations.
Mayne Pharma announced the proposed sale of its Metrics Contract Services business for US$475 million. The sale will allow Mayne Pharma to focus on building its dermatology and women's health product portfolios. Mayne Pharma intends to use the majority of the sale proceeds to repay debt and return excess funds to shareholders through initiatives like a capital return or special dividend. The sale is expected to strengthen Mayne Pharma's balance sheet and financial flexibility.
This document provides an overview of Clorox's FY16 Q4 investor deck. Some key points:
- Clorox has an advantaged portfolio with over 80% of sales from #1 or #2 share brands across cleaning, household, lifestyle, and international categories.
- Innovation is delivering 3%+ annual sales growth and Clorox is focusing on 3D innovation to drive demand.
- Digital transformation and eCommerce are areas of focus as those channels grow.
- International represents 17% of sales and provides growth opportunities in mid-sized countries.
- For FY17, Clorox expects 2-4% sales growth, 25-50bps EBIT margin improvement, and
The document provides an overview of Clorox's Q4 2016 investor deck. Key points include:
- Over 80% of Clorox's sales come from #1 or #2 share brands positioned in mid-sized categories.
- Clorox has an advantaged portfolio supported by consumer megatrends like health and wellness.
- Clorox is driving growth through initiatives like increased brand investments, innovation, and expansion into new categories and markets internationally.
- Digital transformation is a key focus, with Clorox increasing investments in digital media and using technology to improve consumer engagement and ROI.
Udit Batra, CEO of Life Science at Merck KGaA, presented at the UBS Global Healthcare Conference in New York on May 23, 2016. Merck KGaA is a leader in the life science industry with a portfolio of three high-tech businesses: Life Science, Performance Materials, and Healthcare. The integration of the Sigma-Aldrich acquisition is on track to deliver cost synergies while maintaining sales momentum in the Life Science business. Merck KGaA expects mid-single digit organic growth in Life Science in 2016, driven primarily by the Process Solutions business unit.
O documento fornece informações sobre a Profarma, incluindo sua história, estrutura organizacional, realizações recentes, planos de capitalização e sinergias entre suas divisões de distribuição e varejo. O documento também apresenta métricas financeiras e operacionais das principais aquisições da empresa.
- Profarma's 3Q17 earnings release discusses financial results, capital allocation strategy, and division performances. Key highlights include consolidated gross revenue growth of 4.5% and a shortened consolidated cash cycle. The Retail Division accounted for 55% of gross profit versus 40% in 3Q16. Pharma distribution sales decreased 6.6% year-over-year. Net income was adjusted for non-recurring expenses from restructuring. Capex was primarily for IT, machinery, and equipment while net debt declined.
O documento resume os principais resultados financeiros do 3T17 do Grupo Profarma. Destaca o crescimento de 4,5% na receita bruta consolidada, a redução de 16 dias no ciclo de caixa para 35 dias e o aumento da participação do varejo no lucro bruto consolidado para 55%. Também ressalta iniciativas de realocação de capital e redução de custos nas diversas divisões visando aumentar a rentabilidade.
O documento resume o desempenho financeiro da empresa no 2T17, com destaque para:
- Crescimento de 6,7% na receita total consolidada, impulsionada por alta de 55,4% no segmento varejo;
- Melhora no lucro líquido ajustado consolidado de R$2,9 milhões em relação ao trimestre anterior;
- Inauguração em setembro de um novo centro de distribuição no Rio de Janeiro, com investimento de R$40 milhões.
1. Profarma's consolidated sales grew 8.1% in 1Q17, driven by a 56.7% increase in retail sales. The pharma distribution division saw a 9.3% rise in gross profit and a 5% increase in EBITDA.
2. Specialties sales increased 12.8% in 1Q17, with operating expenses declining 1.2 percentage points. The independent customers segment in pharma distribution grew 19.9%.
3. The retail division saw gross margin increase 0.9 percentage points to 30.5% and adjusted EBITDA rise 17.1%. The Rosario stores reported a 75% increase in average monthly sales per store.
O documento resume o desempenho da empresa no 1T17, com crescimento de vendas de 8,1% e redução do endividamento. As principais divisões tiveram evolução nos indicadores, com destaque para o crescimento de 56,7% nas vendas do segmento varejo.
The document summarizes Profarma's capital allocation strategy and performance in 2016. In 2016, Profarma achieved gross revenues of R$5.5 billion, up 12.5% year-over-year. EBITDA was R$144.6 million with a margin of 2.6%. Acquisitions of Rosário and remaining stakes in other companies contributed to growth. The company's diversified business model across pharmaceutical distribution, retail drugstores, and specialty products enhances competitiveness and synergies.
Em 2011, a Companhia decidiu diversificar suas atividades para além da distribuição farmacêutica em busca de maiores retornos. Desde então, realizou várias aquisições de empresas de especialidades e varejo farmacêutico. Em 2016, adquiriu a Rosário, ampliando sua atuação no varejo.
The document summarizes financial information for a Brazilian pharmaceutical company for the third quarter of 2016. It reported consolidated gross revenues of R$1.367 billion for the quarter, a 3.7% increase year-over-year. The retail segment saw a 1.9% decrease in EBITDA compared to the previous year. Specialties sales increased 19.9% year-over-year while distribution sales grew 3.0%. The company's net debt to EBITDA ratio was 3.1x for the quarter.
O documento resume os resultados financeiros da Profarma no 3T16, destacando:
1) Crescimento de 3,7% na receita bruta consolidada em relação ao 3T15;
2) Aumento de 12,3% no lucro bruto da distribuição farmacêutica;
3) Incremento de 19,9% na receita bruta de especialidades e de 1,1 ponto percentual na margem bruta.
Esta apresentação descreve a aquisição da rede de farmácias Rosário pelo Grupo Profarma. A aquisição da rede líder na região Centro-Oeste por R$ 173 milhões permitirá ao Grupo Profarma expandir sua atuação no varejo farmacêutico e capturar sinergias operacionais.
The document summarizes Profarma's 2Q16 earnings release. Key highlights include:
- Consolidated pro-forma gross revenue increased 15.2% and EBITDA rose 59.8% to R$60.2 million.
- Retail sales grew 10.5% and EBITDA increased 50.1% to R$9.8 million. Specialties sales rose 41.9% and EBITDA grew 80% to R$5.1 million.
- Pharmaceutical distribution sales grew 11.4% and EBITDA increased 59% to R$45.1 million, the best performance in 7 years.
Este documento fornece um resumo dos resultados financeiros do 2T16. Destaca o crescimento de 15,2% na receita bruta consolidada e aumento de 59,8% no Ebitda consolidado. Também destaca o desempenho por divisão, com crescimento de vendas de 11,4% na Distribuição Farma, 41,9% nas Especialidades e 10,5% no Varejo.
Este documento apresenta uma análise da dinâmica positiva do setor farmacêutico global e brasileiro nos últimos anos. (1) O mercado global de medicamentos deve alcançar US$ 1,3 trilhões até 2018, impulsionado principalmente pelos mercados emergentes. (2) No Brasil, o mercado farmacêutico tem crescido acima do PIB nos últimos anos, apoiado por fatores demográficos e estruturais. (3) A distribuição e o varejo farmacêutico brasileiros também apresentaram forte
Este documento apresenta uma análise da dinâmica positiva do setor farmacêutico global e brasileiro nos últimos anos. (1) O gasto global com medicamentos deve alcançar US$ 1,3 trilhões até 2018, impulsionado principalmente pelos mercados emergentes. (2) No Brasil, o mercado farmacêutico tem crescido acima do PIB nos últimos anos, apoiado por fatores demográficos e econômicos. (3) A distribuição e o varejo farmacêutico brasileiros também apresentaram forte
O documento apresenta os resultados financeiros do primeiro trimestre de 2016 de uma empresa de distribuição farmacêutica. Destaca-se:
1) Crescimento de 16,9% na receita bruta consolidada;
2) Aumento de 31% no EBITDA consolidado, atingindo R$ 25,8 milhões;
3) Redução no ciclo de caixa consolidado para 32,9 dias.
The document provides an earnings release and financial highlights for Profarma's 1Q16 results. Some key points include:
- Gross revenue increased 16.9% to R$1.338 billion driven by growth across all divisions.
- Consolidated EBITDA rose 31.0% to R$25.8 million with an EBITDA margin of 2.2%.
- The pharmaceutical distribution division saw a 17.0% revenue increase and 16.5% EBITDA growth.
- Specialties revenue grew 38.8% and EBITDA rose 82.9%.
- Retail sales increased 12.4% while EBITDA grew 81.7% to R$3.5
O documento resume o desempenho financeiro da empresa no quarto trimestre e ano de 2015. A receita bruta consolidada cresceu 10,5% no ano, com destaque para o crescimento de vendas na divisão de especialidades de 25,9% e no varejo de 16,1%. O EBITDA consolidado aumentou 31,4% em 2015, atingindo R$ 114,7 milhões.
The document provides highlights and financial results for Profarma's 3Q15 earnings release. Some key points:
- Gross revenue increased 13.2% year-over-year on a consolidated pro-forma basis.
- Consolidated EBITDA rose 9.2% to R$29.1 million with operating expenses falling 0.5 percentage points.
- The Retail division saw sales increases of 15.8% at Drogasmil and 7.1% at Tamoio, with same-store sales up 11.6% and 6.3% respectively.
- Specialties division sales increased 23.7% and EBITDA rose 151.3% to R$5.
O documento resume o desempenho financeiro da empresa no 3T15. Destaca-se: 1) Crescimento de 13,2% na receita bruta consolidada; 2) Aumento de 9,2% no EBITDA consolidado; 3) As divisões de especialidades e varejo apresentaram forte crescimento nas vendas.
3. 3
• Profarma had one more year of great achievements and maybe one of the most important in its history. It was a year of
change in the Company’s business model, with the acquisition of 100% of Drogasmil/Farmalife and 50% of Drogarias
Tamoio chains, both in January 2013, when Profarma broke into the pharmaceutical retail market. As a result, the
Company has become an even more complete, integrated and vertically platform in the pharmaceutical market;
• On March 24, 2014, Profarma started a strategic association in which U.S. wholesaler AmerisourceBergen will be able to
own up to 19.9% of Profarma’s capital stock through the subscription of new shares in connection with a capital increase
at R$ 22.50 / share yet to be made. This amount will be mainly used to fund the Company’s growth strategy;
• Additionally, the companies will be creating Profarma Specialty, a joint venture in which each company will own a 50%
equity state, to increase Profarma’s current share in the hospital and specialties market;
• The capital subscription resulting from these two operations will amount R$ 250.0 million to R$ 400.0 million;
• The Profarma’s shares (PFRM3) were priced at R$ 18.64 at the close of the year, up 28.6% year-over-year, with an
average daily trading volume of R$ 4.0 million, up significantly 273.5% in relation to 2012.
Highlights in the Period
3
Profarma | Earnings Release 4Q13 and Year
5. 5
5
Profarma | Earnings Release 4Q13 and Year
(R$ million and % Net Revenues)
Gross Profit and Revenues from Services to Suppliers
4Q12
39.7
50.7
2013
122.6
307.5
10.7%
13.4%
4Q13
23.6
92.3
12.4%
11.0%
2012
150.6
204.7
Gross Profit Revenues from Services to Suppliers Gross Profit Margin(%)
6. 6
6
Profarma | Earnings Release 4Q13 and Year
(R$ million and % Net Revenues)
Operating Expenses - SGA
4Q12
67.1
2013
333.2
7.9% 7.9%
12.3%
4Q13
105.7
2012
256.6
9.6%
7. 7
7
Profarma | Earnings Release 4Q13 and Year
(R$ million and % Net Revenues)
Ebitda and Ebitda Margin
4Q12
18.8
2013
95.8
2.2%
2.8%
1.7%
4Q13
14.8
2012
92.2
2.9%
8. 8
8
Profarma | Earnings Release 4Q13 and Year
Net Financial Expenses
(R$ million and % Net Revenues)
4Q12 4Q13 2013
6.3
28.6
1.8%
0.9%
0.7%
15.7
2012
56.0
1.6%
9. 9
9
Profarma | Earnings Release 4Q13 and Year
(R$ million and % Net Revenues)
Net Profit
4Q12
4Q13
2013
7.8
40.6
0.9%
0.6%
- 0.5%
(4.6)
2012
20.4
1.3%
11. 11
11
Profarma | Earnings Release 4Q13 and Year
* Average
(1) Average of Gross Revenues in the Quarter
(2) Average of COGS in the Quarter
(3) Average of COGS in the Quarter
Cash Cycle - Days *
Accounts Receivable (1)
Inventories (2)
Accounts Payable (3)
4Q134Q12
54.7
45.8
56.4
47.5
46.3
51.0
48.2
52.9
12. 12
12
Profarma | Earnings Release 4Q13 and Year
Indebtedness:
Net Debt and Net Debt / Ebitda*
(R$ million)
2013
458.5
4.8x
2012
168.7
1.8x
* Ebitda = accumulated last 12 months
13. 13
13
Profarma | Earnings Release 4Q13 and Year
(R$ million and % Net Revenues)
Capex
4Q12 4Q13 2013
2.2
12.3
0.3% 0.4%
1.0%
9.0
2012
10.8
0.3%
14. 14
14
Service Level
(Units served / Units Requested)
Logistics E.P.M.
(Errors per Million)
4Q12
89.2%
4Q13
88.9%
2013
89.6%
2012
87.8%
4Q12
65.0
4Q13
94.0
2013
107.7
2012
94.0
Profarma | Earnings Release 4Q13 and Year
15. 15
Gross Revenues
R$ million
95.2
Op. Exp.
Total
Gross
Margin
Ebitda
Margin
Net
Margin
21.9%
30.4%
5.6% 3.6%
Financial DataTamoio – 4Q13
(R$ million e % Gross Revenues)
59
4
6.6%
25.85
537.8
20.2
# of stores
Store Openings
1
SSS Mature Stores (more than 36 months)
Average Ticket (in reais)
Monthly Average Store's Sales
Revenues per Employee
1- Same Store Sales
9.4%1SSS
Operational Data Tamoio – 4Q13
(R$ thousands)
15
Profarma | Earnings Release 4Q13 and Year
16. 16
16
Profarma | Earnings Release 4Q13 and Year
Gross Revenues Breakdown
Tamoio – 4Q13
43.8%
33.0%
15.7%
7.4%
(R$ million and % Net Revenues)
Gross Profit
Health and Beauty Products Branded OTCGeneric
1Q13
9.6
4Q13
19,8
22.9%
29,9%
17. 17
17
Profarma | Earnings Release 4Q13 and Year
Turnover - PFRM3 PFRM3 IBOV Index IGCX Index
Stock Performance
100
28.6
-2.0
-15.5
100
19. 19
Strategic Association | Transaction Rationale
• Creation of the brand Profarma Specialty;
• Each company will contribute with what it does best: growth in specialties market, focusing on distribution
services, innovation and tecnology;
• The companies will support each other to accelerate growth, while drawing on the synergies and expertise in
Pharmaceutical Distribution and Specialties Distribution.
19
Relationships
New Business Opportunities
Growth
Platform for Future Growth
Diversification
New Products & Services
Recognition
Strengthening the Brand
+
20. 20
Specialties | Creation of Profarma Specialty
20
SegmentIndustry Origin
Dermatology
Vaccines
Hospital
Private /
Distribution
Inside Profarma
Pharma Business
Oncology
Vaccines
Hospital
Private & Public /
Distribution
Acqusiition
60% in Nov/11
100% in Sep/13
Breast Implants
Dermatology
Arthritis
Hormones
Private /
Specialties
Acquisition
80% in Dec/12
100% Option
Oncology
Dermatology
Breast Implants
Vaccines
Other
Private & Public /
Distribution &
Pharmacy
Joint Venture
22. 22
AmerisourceBergen Corporation | Overview
22
One of the largest global pharmaceutical services companies dedicated exclusively to increasing supply chain
efficiency:
23. 23
AmerisourceBergen Corporation | Overview
Company Overview
• AmerisourceBergen is one of the world's largest
pharmaceutical services companies serving the United
States, Canada and selected global markets;
• Focused on the pharmaceutical supply chain. Servicing both
pharmaceutical manufacturers and healthcare providers, the
Company provides drug distribution and related services;
• The pharmaceutical distribution business operates under the
business units of AmerisourceBergen Drug Corporation,
AmerisourceBergen Specialty Group, AmerisourceBergen
Consulting Services and World Courier;
• AmerisourceBergen Specialty Group leads the market in
oncology, plasma-derivative and biotech product distribution
in USA and Canada;
• AmerisourceBergen Specialty Group is a True Market
Leader, serving over 4,500 community oncologist practices,
is umber one in most physician specialties and in dialysis,
the number one distributor of blood derivatives, and also
have over 35,000 active customers for vaccines, biologicals
and injectables.
U$ billion
Revenues
78.7
2011
9.6%
78.1
2012
11.5%
88.0
2013
11.7%
Diverse Mix of Revenues*
Retail
Specialty
Health
Systems
Alternate
Sites
Manufacturer
Services
23
*Estimated FY2014 Revenues
24. 24
AmerisourceBergen Corporation | Services & Solutions
24
DEVELOPMENT PRE-LAUNCH LAUNCH HIGH-GROWTH MARKET MATURITY
Global Clinical Trial Logistics
Trial Packaging & Laboratory Services
Analytics & Busines Intelligence
Contract & Specialized Production Packaging Services
Health Economics & Outcomes Research
Reimbursement Services & Market Analysis
Physician Networks
Clinical Hotlines
Specialty Pharmacy Services
Outsourced Logistics
Patient Adherence & Compliance Services
Medical Science Liaison Programs
Oncology Product Distribution
Blood Plasma & Nephrology Product Distribution
Vaccine, Injectable & Biological Product Distribution
Generics Strategy
Expertise across Pharmaceutical Life Cycle:
Brand Services & Managed Markets Solutions
26. 26
Strategic Association | Transaction Summary
26
Strategic alliance formed by two operations:
Capital Increase
R$ 335.6 million
Primary:
R$ 40 million
Secondary:
R$ 21 million
Joint VentureCapital Increase
Market AmerisourceBergen
56%
R$ 190
million
44%
R$ 146
million
27. 27
2
1
Strategic Association | Transaction Summary
27
• AmerisourceBergen Corporation may come to hold up to 19.9% of Profarma’s capital, through a
subscription of capital increase of R$335.6 million via assignment of the subscription rights attributed
to the shares held by BMK (Profarma’s holding and parent company);
• The rights issue will be carried out at the price of R$ 22.50 / share;
• The amount will be used to finance the Company’s growth strategy;
CapitalIncreaseJointVenture
• Profarma and AmerisourceBergen Corporation will create Profarma Specialty, a JV in which each
company holds a 50% interest;
• Profarma will contribute its operational assets, which are formed by Prodiet, Arpmed and its Hospital
and Vaccine Division, and AmerisourceBergen Corporation will make a primary capital injection of R$ 40
million and a secondary injection of R$ 21.3 million.